Cambium Bio Ltd, formerly Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. The company develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology, and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. The company's product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing.
No Data